Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1722924 | 0.83 | MTNR1A (0.33) | CNR1CNR2MTNR1AMTNR1BEPHX1 | |
| SCHEMBL1710785 | 0.82 | PNMT (0.32) | — | |
| SCHEMBL610036 | 0.80 | OPRK1 (0.36) | CNR1CNR2MTNR1AMTNR1BEPHX1 | |
| SCHEMBL610037 | 0.80 | OPRK1 (0.36) | CNR1CNR2MTNR1AMTNR1BEPHX1 | |
| SCHEMBL10237441 | 0.80 | OPRK1 (0.36) | CNR1CNR2MTNR1AMTNR1BEPHX1 | |
| SCHEMBL3185692 | 0.78 | CNR1 (0.41) | CNR1CNR2MTNR1AMTNR1BEPHX1 | |
| SCHEMBL1710744 | 0.78 | GAA (0.36) | CNR1CNR2MTNR1AMTNR1BEPHX1 | |
| SCHEMBL1722448 | 0.77 | CYP3A4 (0.37) | CNR1CNR2MTNR1AMTNR1BEPHX1 | |
| SCHEMBL1724248 | 0.77 | ITGB1 (0.34) | CNR1CNR2MTNR1AMTNR1B | |
| SCHEMBL3387507 | 0.76 | ITGB1 (0.34) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, MPST, CLN6 | CNR1 3211/4885CNR2 3404/4885MTNR1A 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.